Akari Therapeutics (AKTX) Tax Provisions (2025 - 2026)

Akari Therapeutics' (AKTX) quarterly Tax Provisions came in at -$859000.0 in Q1 2026, down 1110.59% quarter-over-quarter from $85000.0 in Q4 2025.

Akari Therapeutics (AKTX) Tax Provisions (2025 - 2026) Analysis & Trends

Akari Therapeutics has disclosed Tax Provisions across 2 years of filings, most recently posting -$859000.0 for Q1 2026.

Tax Provisions for Q1 2026 came in at -$859000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.9 million (changed N/A YoY), and the FY2025 annual result was -$1.0 million, changed N/A from the prior year.
Tax Provisions came in at -$859000.0 for Q1 2026 at Akari Therapeutics, down from $85000.0 in the prior quarter.
In the past five years, Tax Provisions ranged from a high of $85000.0 in Q4 2025 to a low of -$1.1 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-11.20 Mn
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-859,000.00
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	216,000.00
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	221.50 Mn
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Regeneron Pharmaceuticals	63.59 Bn	54.83 Bn	3.31 Bn	104.00 Mn

Download Data